Name | disodium,5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate |
---|---|
Synonyms |
BTA-243
CL 316,243 disodium 5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxazole-2,2-dicarboxylate disodium 5-[(2R)-2-{[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}propyl]-1,3-benzodioxole-2,2-dicarboxylate Disodium (R,R)-5-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)-amino)propyl)-1,3-benzodioxole-2,3-dicarboxylate |
Description | CL316243 is a highly potent selective β3-adrenoceptor agonist with a EC50 of 3 nM, but is an extremely poor to β1/2- receptors[1].CL316243 is a effective stimulant of adipocyte lipolysis and increases brown adipose tissue thermogenesis and metabolic rate[2]. CL316243 has the potential for the treatment obesity, diabetes and urge urinary incontinence[3]. |
---|---|
Related Catalog | |
Target |
EC50: 3 nM (β3-adrenoceptor)[1] |
In Vitro | CL 316243 displays binding affinities with IC50 values of 0.6 μM and 1 μM for rat heart and rat soleus muscle respectively[1]. CL 316243 inhibits spontaneously contracting, isolated rat detrusor strips in a concentration dependent manner with a mean concentration inhibiting 50% of maximal response of 2.65 nM[3]. |
In Vivo | CL316243 disodium (subcutaneously injection; 0.1 mg/kg/day; once a day; 1 weeks) elevates the mRNA and protein expression levels of UCP1 in BAT, irrespective of diet[2]. Animal Model: Male C57BL/6J mice fed with high-fat diets (HFD; 45%-kcal fat) or a control diet (ND; 10%-kcal fat) for 14 weeks[2] Dosage: 0.1 mg/kg/day Administration: once a day; 1 weeks Result: Exhibited a premium effect of obesity in mice. |
References |
Boiling Point | 689.5ºC at 760 mmHg |
---|---|
Molecular Formula | C20H18ClNNa2O7 |
Molecular Weight | 465.79200 |
Flash Point | 370.8ºC |
Exact Mass | 465.05700 |
PSA | 130.98000 |
Vapour Pressure | 5.86E-20mmHg at 25°C |